Regenerative Medicine Market in the US 2017-2021

Overview of the regenerative medicine market in the US

According to Technavio’s market research report, the regenerative medicine market in the US will grow rapidly at a CAGR of close to 24% during the forecast period. The increasing governmental funding in regenerative medicines is one of the key drivers that will stimulate growth in the market from 2017 to 2021. Governmental organizations are supporting the research and clinical trials of regenerative medicines due to the growing importance of regenerative medicines and the inability of research institutes and small companies to afford the research and developmental activities. In the US, most of the funds are provided by the National Institute of Health (NIH) and California Institute of Regenerative Medicine (CIRM) to conduct stem cell research. At present, the NIH is studying the disease mechanism using the induced pluripotent stem cells (iPSc) technology.

The growing focus on gene therapy is one of the key trends that will be witnessed in the regenerative medicine market in the US during the projected period. Researchers in the US are conducting gene therapy clinical trials to develop cancer therapy for hemophilia and thalassemia. The approval of gene therapy products in region such as EMEA and APAC will have a positive impact on the development of regenerative therapy.

Competitive landscape and key vendors

The regenerative medicine market in the US is highly competitive and fragmented due to the presence of a number of large, medium, and small-sized companies. These vendors are increasingly competing against each other based on factors such as aggressive pricing, product differentiation, capital support for product upgrading, and distribution partnerships.

Key vendors in this market are -

• Acelity
• Medtronic
• MiMedx
• Organogenesis
• Zimmer Biomet

Other prominent vendors in the market include ACE Surgical Supply, Acera Surgical, Acologix, Advanced Biologics, AlloCure, AlloSource, Alphatec Spine, ANTEROGEN, Antibe Therapeutics, Astellas Pharma, Athersys, Avita Medical, AxoGen, Bacterin International, Baxter, Bellicum Pharmaceuticals, BioCardia, Biogen, BioRestorative Therapies, Biostage, Bio-Tissue, BioTissue, bluebird bio, BONESUPPORT, BrainStorm Cell Therapeutics, Caladrius, Calimmune, Capricor Therapeutics, CELGENE, Cell Medica, Cell Therapy, CellBioMed, CellSeed, Celyad, CESCA THERAPEUTICS, CTM CRC, CryoLife, Cynata, Cytori Therapeutics, Dendreon Pharmaceuticals, DiscGenics, Fate Therapeutics, Fibrocell Science, Forticell Bioscience, Fortress Biotech, FUJIFILM Holdings, Gamida Cell, Geron, GlaxoSmithKline, Healthpoint, Histogen, Histogenics, Holostem Terapie Avanzate, Humacyte, Immunocellular Therapeutics, Integra LifeSciences, Intercytex, InVivo Therapeutics, iSTO Biologics, Janssen Pharmaceuticals, Juno Therapeutics, Juventas Therapeutics, Kiadis Pharma, LifeCell, LifeNet Health, Living Cell Technologies, Lonza, MaxCyte, MEDIPOST, Mesoblast, Nanofiber Solutions, Nanotope, Neuralstem, NewLink Genetics, Northwest Biotherapeutics, NovaRx, Opexa Therapeutics, ORGANOVO HOLDINGS, Orteq, Orthofix Holdings, Osiris Therapeutics, Pfizer, PHARMICELL, Pluristem, Prima BioMed, Q Therapeutics, Regenerex, Regenerys, Regience, Regrow, RENOVA THERAPEUTICS, RepliCel, ReproCELL, RhinoCyte, Rohto Pharma, RTI Surgical, SanBio, Sangamo Therapeutics, Shanghai Sunway Biotech, Shire, Stratatech, SURGILOGIX, Synergistic Technologies, TAKARA BIO, tella, Tissue Genesis, TissueGene, Txcell, VentriNova, Vericel, ViaCyte, and VistaGen Therapeutics.

Segmentation by product and analysis of the regenerative medicine market in the US

• Cell therapy
• Tissue scaffolds

Cell therapy is gaining momentum in the US due to its application in dermatology and cancer therapy. Also, various institutes and research laboratories in the US are increasingly focusing on the development of regenerative medicine by conducting studies on biological products that can be used for cell therapy. This will drive the demand for cell therapy products in the US in the forthcoming years.

Segmentation by end-user and analysis of the regenerative medicine market in the US

• Hospitals
• ASCs
• Regenerative medicine centers

The patient pool highly prefers hospitals over other health care centers because they are partnering with regenerative medicine manufacturing companies. This enables hospitals to provide cell therapy and tissue scaffolds to improve patient care and treatment. The rising number of wound treatment, craniomaxillofacial surgery, knee replacement cases, and soft tissue repair will also boost the influx of patients in hospitals.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the regenerative medicine market in the US?
• What are the key market trends impacting the growth of the regenerative medicine market in the US?
• What are the challenges to market growth?
• Who are the key vendors in the regenerative medicine market in the US?
• What are the market opportunities and threats faced by the vendors in the regenerative medicine market in the US?
• What are the trending factors influencing the market shares of the US?
• What are the key outcomes of the five forces analysis of the regenerative medicine market in the US?

Technavio also offers customization on reports based on specific client requirement